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ABSTRACT 
Objective: The aim of the present study is to evaluate the plasmid profile and curing in extended spectrum beta-lactamases (ESBL) producers and 
know the association of biofilm formation among ESBLs.  
Methods: Standard disk diffusion method (Kirby Bauer’s method) was performed to know the sensitivity and resistance patterns for commonly 
used antibiotics and clinical laboratory standard institute (CLSI) recommended confirmatory phenotypic method was used to confirming ESBL 
producers. 56 ESBL producers were subjected to plasmid profiling and curing. The tube (qualitative) and microtitre (quantitative) methods were 
performed to detect the biofilm formation. 
Results: In all ESBL producers, a single plasmid was found with approximately 21, 226 bp. After plasmid curing, the resistance patterns against the 
third generation cephalosporin group of antibiotics were transformed into susceptible for all bacterial isolates. In tube method, 11 (19.64%) 
isolates were strong adherent, 08 (14.28%) were either weakly adherent or non-biofilm producers. In the microtitre plate method, 09 (16.07%) 
were considered as positive, and 47 (83.92%) were considered as negative for biofilm formation. 
Conclusion: We found a single resistant plasmid in all isolates and after curing of plasmids, the transformation of resistance to susceptibility against 
third generation drugs were observed. So, we concluded that ESBL mediated antimicrobial resistance mechanisms in Acinetobacter spp. is maybe 
plasmid-mediated in the tested isolates. However, there was no association found between biofilm producers and ESBLs, this baseline information 
will be helpful to study more in this area.  
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INTRODUCTION 
Acinetobacter spp. is one of the emerging opportunistic and 
multidrug-resistant (MDR) bacteria among NFGNB (Non 
Fermentative Gram Negative Bacteria) causing various infections 
such as pneumonia, urinary tract infection, endocarditis, surgical 
site infection, meningitis, and septicaemia, particularly in immune-
compromised patients [1]. Extended-spectrum beta-lactamases 
(ESBLs) are enzymes produced by gram negative bacteria including 
Acinetobacter spp. that inactivates extended-spectrum 
cephalosporins and other beta-lactam antimicrobial agents and are 
inhibited by clavulanic acid, sulbactum or tazobactam [2]. ESBLs can 
be plasmid mediated resistance mechanism. The plasmid may 
spread antibiotic resistance genes to their host bacteria by various 
mating processes and replicates independently of the host 
chromosome. Their size varies from 1 to over 1,000 Kb. The number 
of plasmids can range from one to thousands under some 
circumstances [3]. Biofilm is the surface-attached (sessile) 
community of microorganisms growing embedded in a self-
produced matrix of extracellular polymeric substances (EPS). 
Typically biofilm shows an increased antimicrobial resistance as 
compared to plank tonic bacteria [4]. Frequently, the biofilm 
production should be found in the clinically relevant infections, and 
the biofilm producers should be resistance to the commonly used 
antibiotics and also a variety of disinfectants [5]. This study was 
designed to know the nature of plasmid as an antibiotic resistance 
marker in ESBLs and biofilm detection among ESBL producing 
Acinetobacter species. 
MATERIALS AND METHODS 
During 8 mo period (May 2013-December 2013), 56 ESBL producing 
Acinetobacter spp. (isolated from the clinical specimens of routine 
diagnosis) were obtained in the Department of Microbiology, Sri 
Venkateswara Institute of Medical Sciences, Tirupati. Kirby Bauer’s 
method [6] was performed to know the resistance pattern. The CLSI 
recommended confirmatory phenotypic method [7] was performed 
to confirm the presence of ESBL production. K. pneumoniae ATCC 
700603 (positive control) and E. coli ATCC 25922 (negative control) 
were used as quality control.  
Isolation and detection of molecular weight of plasmid DNA 
The plasmid DNA from ESBL producing isolates of Acinetobacter spp. 
were isolated using alkaline lysis method described by Sambrook et 
al.[8] The bacterial cultures were grown in LB medium with 
appropriate antibiotic at 37 °C, 150 rpm for 16-18 h. After nucleic 
acid precipitation, plasmid pellet was dissolved in 50 µl of TE (10 
mM tris, 1 mM EDTA, pH 8) buffer. Agarose gel electrophoresis was 
performed on 0.8 per cent (w/v) agarose prepared in TBE buffer. 
The plasmid profiles were documented under UV light in Gel 
Documentation System. (fig. 1)  
Curing of plasmid DNA 
The curing of plasmid DNA was performed in ESBL producing 
strains of Acinetobacter spp. by the method as described by 
Deshpande et al.[9]. The efficiency of plasmid curing was expressed 
as a number of colonies with cured phenotype per 100 colonies 
tested. In cured strains, the antibiotic sensitivity test (disc diffusion 
method) was repeated to check the presence or loss of resistance 
character and additionally, agarose gel electrophoresis was 
performed with the plasmid DNA preparation of respective culture 
to confirm the physical loss of plasmids.  
Biofilm detection by tube method 
We screened all isolates for the biofilm formation by tube method 
(qualitatively) as described by Christensen et al. [10]. Brain-heart 
infusion (BHI) was inoculated with loopful of test culture from 
overnight culture plates and incubated for 24 h at 37 °C. Then, tubes 
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were decanted and washed with PBS (pH 7.3) and dried than tubes 
were stained with crystal violet (0.1%). Excess stain was removed 
with PBS and tubes were washed with deionized water. Tubes were 
than dried in inverted position and observed for biofilm formation. 
Biofilm formation was considered positive when a visible film lined 
the wall and bottom of the tube. Ring formation at the liquid 
interface was not indicative of biofilm formation. Tubes were 
examined and the amount of biofilm formation was recorded as 
strongly adherent (strongly positive), weekly adherent (week 
positive) and non-adherent (negative). Experiments were 
performed in triplicate and repeated three times. 
Biofilm detection by microtitre method 
Micro-titre method (quantitatively) [10] was performed to screen 
the biofilm formation. A 1:100 dilution of overnight broth culture of 
the test organism was inoculated in BHI broth with 2% sucrose and 
transferred to 96 well polystyrene flat-bottomed microtitre plates.  
 
 
Fig. 1: Plasmid profile of ESBL producing Acinetobacter spp M: λ 
DNA (EcoR1+Hind III digested); 1,2,3,4 and 5: presence of 
plasmid DNA 
 
After incubation at 37 °C, washed and air dried then stained with 
crystal violet solution, the glacial acetic acid was added to the wells 
and optical density was read at 490 nm. The optical density (OD) 
greater than 0.120 was considered for biofilm formation. The biofilm 
positive control strain was maintained [11]. 
All ESBL positive samples were sensitive to tegecyclin (100%) 
followed by polymixin-B (91.07%) and imipenem (66.66%) and 
100% resistance to third generation cephalosporins which includes 
cefotaxime, ceftazidime, cefepime and monobactam includes 
azotreonam and resistance pattern for other antibiotics were shown 
in table 1. 
 
 
Fig. 2: Showing biofilm detection in tube method, PC: Positive 
Control; NC: Negative Control; SA: Strong Adherent; WA: Weak 
Adherent; NA: Non-Adherent 
 
 
Fig. 3: Showing biofilm detection in microtitre method, PC: 
Positive Control; NC: Negative Control; P: Positive; N: Negative 
 
The analysis of plasmid in ESBL producing strains revealed the 
presence of plasmid DNA with an approximate molecular weight of 
21,226 bp in all isolates (fig. 1). Most of the isolates showed thick 
blue ring at the liquid–air interfaces (fig. 2). In tube method, 11 
(19.64%) isolates were strong positive, 08 (14.28%) were weakly 
adherent and 37 (66.07%) were non-biofilm producers. Isolates that 
showed weekly adherent were considered as non-biofilm producers. 
In the micro-titre plate method, the 09 (16.07%) were showed OD 
values greater than 0.120 and remaining isolates 47 (83.92%) were 
considered as negative for biofilm formation. were considered as 
negative for biofilm formation (fig. 3). 
 
Table 1: Antibiotic sensitivity pattern of 56 ESBL producing Acinetobacter spp 
Serial number Antibiotic (concentration) Sensitive (%) Intermediate (%) Resistance (%) 
1.  amikacin (30 μg) 16 (28.57) 03 (5.35) 37 (66.07) 
2.  ampicillin (10μg)  00 (0.00) 03 (5.35) 53 (94.64) 
3.  aztreonam(30μg)  00 (0.00) 00 (0.00) 56 (100) 
4.  cefepime(30μg)  00 (0.00) 00 (0.00) 56 (100) 
5.  cefotaxime (30μg)  00 (0.00) 00 (0.00) 56 (100) 
6.  cefoxitin (30μg) 08 (14.28) 03 (5.35) 45 (80.35) 
7.  ceftazidime (30μg)  00 (0.00) 00 (0.00) 56 (100) 
8.  chloramphenicol (30μg)  08 (14.28) 04 (7.14) 44 (78.57) 
9.  ciprofloxacin (5μg) 09 (16.07) 04 (7.14) 43 (76.78) 
10.  co-trimoxazole (25μg)  24 (42.85) 05 (8.92) 27 (48.21) 
11.  gentamicin (30μg) 09 (16.07) 04 (7.14) 43 (76.78) 
12.  imipenem (10μg)  37 (66.07) 08 (14.28) 11 (19.64) 
13.  meropenem (10μg) 40 (71.42) 08 (14.28) 08 (14.28) 
14.  nitilmicin (30μg) 20 (35.71) 00 (0.00) 36 (64.28) 
15.  polymixin-B (300 units) 51 (91.07) 00 (0.00) 05 (8.92) 
16.  tegecyclin (15 μg) 56 (100) 00 (0.00) 00 (0.00) 
17.  piperacillin tazobactum (100/10μg) 13 (23.21) 08 (14.28) 35 (62.5) 
18.  cefaperazone sulbactum (75/10μg) 29 (51.78) 07 (12.5) 20 (35.71) 
19.  amoxy clav (20/10μg)  02 (3.57) 14 (25.00) 40 (71.42) 
 μg: microgram; %: percentage. 
 
DISCUSSION 
Most commonly, extended spectrum beta lactams and other beta 
lactam group of antibiotics have been used to treat gram negative 
bacterial infections including Acinetobacter spp. But the emergence 
of ESBL producing and another beta-lactamase producing organisms 
has been posed a serious threat for their continuing use [12, 13]. The 
nosocomial infections are becoming rising trouble for hospitalized 
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patients [14]. If the antibiotic resistant bacteria, unluckily spread to 
patients in any transmission mode, subsequently susceptible 
microbial flora may also be transformed into the resistant strain or 
susceptible bacteria into resistant, as a result, the risk factors are 
directly or indirectly increases treatment failure. Acinetobacter 
baumannii were highly resistant to a β-lactum group of antibiotics 
which were isolated from the ICU patients [15]. In our study, 
gentamicin resistance was found to be 76.78% which was high as 
compared to the previous study reported by Shafaq Aiyaz Hassan et 
al.,[16] (60%) and low (92.6%) when compared with Iroha et 
al.,[17]. 
The resistance profile of ciprofloxacin among ESBL producers varies 
with geographic regions 13.7% in Canada, 34.8% in France, 34.2% in 
Europe to 65.5% in Western pacific [18]. In our study, 76.78% of 
resistance pattern was documented which was close prevalence to 
(76.5%) reported in Bangladesh [19].  
Treatment options for ESBL producing isolates are available, but 
they are limited. The risk factor of treatment failure is more in 
patients infected with ESBL producers than ESBL non-producers 
[20]. In a previous studies from Pakistan [21] and Bangladesh [19], 
all ESBL producers were sensitive (100%) to carbapenems. The 
carbapenems are used to treat the infections caused by ESBL 
producers, but carbapenem-resistant ESBL isolates have been 
reported from various parts of the world including United States, 
Greece, Korea, Israel, and China [22]. In our study, 19.64% and 
14.28% of resistance were found against imipenem and meropenem 
respectively.  
In a study from Pune, Acinetobacter spp. isolated from human skin 
showed a maximum of three plasmids ranging from 1.5 to 40 kb [23] 
but in our study only single plasmid (approximately 21,226 bp) was 
observed among all ESBL strains isolated from clinical specimens. 
The physical loss of plasmid (after curing) is the evidence for the 
nature of antibiotic resistance marker in the ESBL strains. The cured 
isolates were found sensitive to third generation cephalosporins.  
Microbial biofilms are considered as the virulence factors. In this 
study, the detection of biofilm production in Acinetobacter spp. was 
aimed to verify any association between the biofilm formation and 
ESBLs. The device related nosocomial infection also causes the 
organisms to resist physical and chemical disinfection, often by 
forming a biofilm. Therefore, infections due to bacteria that form 
biofilms are a persistent clinical problem. In a study, both qualitative 
(tube method) and quantitative (microtitre plate) method showed 
30 isolates (60%) as biofilm producers [24]. In the present study, 11 
(19.64%) isolates were considered as strong adherence, 08 
(14.28%) isolates were weak adherence and 37 (66.07%) were 
showed non-adherence by tube method whereas in micro-titre plate, 
09 (16.07%) were considered as biofilm producers and 47 (83.92%) 
were considered as non-bio film producers. However, as adherence 
alone may not complete the cycle of the process of biofilm formation 
and there might be many other mechanisms that could explain 
adherence [25]. So, we categorized isolates that were weakly 
adherent as biofilm negative and this report was suggested that low 
prevalence then Dheepa et al., a study [24]. In another study, it was 
observed that 44% of positive biofilm isolates were isolated from 
wound infections and 30% of biofilm producers were identified 
from patients suffered from pneumonia. This indicates that in the 
wound and respiratory infections, the biofilm may contribute to 
antibiotic resistance [25] and in the same study, both the qualitative 
and quantitative method showed 62% of isolates as strong biofilm 
producers. Fourteen isolates, which were weakly adherent, were 
additionally picked up by the quantitative microtitre assay asserting 
its sensitiveness. 
We concluded that the nature of plasmid plays a major role in 
antibiotic resistance with reference to ESBL mediated resistance. In 
this regard, furthermore, molecular studies to be needed to check 
whether the prevalence of resistance was due to a specific gene or 
multiple genes.  
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